SIREN : 410125124
DEMO INJECTION is a French company founded 29 years ago, specialized in the sector Fabrication d'autres équipements automobiles. Based in CHAMBLY (60230), this company of category ETI shows in 2024 a revenue of 26.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26 356 187 € | 28 895 410 € | 28 236 256 € | 30 276 980 € | 30 146 435 € | 37 757 611 € | 3 433 397 € | 38 079 910 € | 36 971 539 € | 33 277 740 € |
| Net income | -3 674 046 € | -3 027 951 € | -585 487 € | -1 946 135 € | -2 052 568 € | -3 678 464 € | 205 128 € | 2 386 490 € | 1 024 084 € | 1 028 240 € |
| EBITDA | -1 460 875 € | -923 570 € | -1 115 408 € | -635 381 € | -1 011 882 € | -1 282 846 € | 175 196 € | 2 284 090 € | 2 546 856 € | 1 786 830 € |
| Net margin | -13.9% | -10.5% | -2.1% | -6.4% | -6.8% | -9.7% | 6.0% | 6.3% | 2.8% | 3.1% |
In 2024, DEMO INJECTION achieves revenue of 26.4 M€. Activity remains stable over the period (CAGR: -2.6%). Slight decline of -9% vs 2023. After deducting consumption (6.2 M€), gross margin stands at 20.2 M€, i.e. a rate of 77%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -1.5 M€, representing -5.5% of revenue. Warning negative scissor effect: despite revenue change (-9%), EBITDA varies by -58%, reducing margin by 2.3 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -3.7 M€ (-13.9% of revenue), which will impact equity.
26 356 187 €
20 202 546 €
-1 460 875 €
-3 358 565 €
-3 674 046 €
-5.5%
The debt ratio (= Financial debt / Equity x 100) stands at 92%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 30%. The balance between equity and debt is satisfactory.
92.056%
29.632%
-6.894%
-3.877
25.9%
In 2024, the debt ratio of DEMO INJECTION (92.06) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of DEMO INJECTION (29.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of DEMO INJECTION (-3.88) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 168.42. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
168.424
-43.452
In 2024, the liquidity ratio of DEMO INJECTION (168.42) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of DEMO INJECTION (-43.5x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 126 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 75 days. The gap of 51 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 61 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 171 days of revenue, i.e. 12.5 M€ to permanently finance. Over 2015-2024, WCR increased by +44%, requiring additional financing.
12 544 491 €
126 j
75 j
61 j
171 j
Indicative estimate only : the number of comparable transactions in this sector is limited (22 transactions). This range of 19 629 623€ to 41 132 697€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 22 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare DEMO INJECTION with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication d'autres équipements automobiles
The revenue of DEMO INJECTION in 2024 is 26.4 M€.
DEMO INJECTION recorded a net loss in 2024.
The headquarters of DEMO INJECTION is located in CHAMBLY (60230), in the department Oise.
The tax return of DEMO INJECTION is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DEMO INJECTION operates in the sector Fabrication d'autres équipements automobiles (NAF code 29.32Z). See the 'Sector positioning' section above to compare the company with its competitors.